Anti NOTCH 1  

Immunohistochemistry of Rabbit anti-Notch1 antibody. Tissue: Exocrine glands of human pancreas. Fixation: FFPE. Primary antibody: Notch1 antibody at 1:200. Staining: moderate to strong membranous staining and faint to moderate cytoplasmic staining. Islets showed faint staining.

Dot Blot of Rabbit anti-Notch 1 (Cleaved N Terminal) (Human Specific) Antibody. Antigen: Row 1 - Notch 1 Peptide (Cleaved N Terminal) Row 2 - Notch 1 (Intra) Peptide. Load: Lane 1 - 200 ng Lane 2 - 66.67 ng Lane 3 - 22.22 ng Lane 4 - 7.41 ng Lane 5 - 2.47 ng. Primary antibody: Rabbit anti-Notch 1 (Cleaved N Terminal) (Human Specific) Antibody at 1:1,000 for 60 min at RT. Secondary antibody: HRP Rabbit Secondary at 1:40,000 for 30 min at RT. Block: MB-070 for 1 HR at RT.

Rabbit anti-Human NOTCH 1 (Cleaved N Terminal) was used at a 1:500 dilution to detect mouse Notch 1 by Western blot. Equivalent amounts of lysates from transiently transfected 293 cells expressing recombinant myc-tagged mouse Notch constructs were electrophoresed and transferred to membrane using standard methods. A reaction with diluted primary antibody was followed by washing; reaction with a 1:10,000 dilution of HRP conjugated Gt-a-Rabbit IgG (611-103-122), and color development. Lane M: Mol wt markers. Lane 1: No transfection. Lane 2: N1 (mouse deleted extracellular domain)-myc. Lane 3: N1 (mouse intracellular domain)-myc. Lane 4: N2 (mouse deleted extracellular domain)-myc. Lane 5: N2 (mouse intracellular domain)-myc. Lane 6: N3 (mouse deleted extracellular domain)-myc. Lane 7: N3 (mouse intracellular domain)-myc. Lane 8: N4 (mouse deleted extracellular domain)-myc. Lane 9: N4 (mouse intracellular domain)-myc. Lane 10: N1 (mouse deleted extracellular domain)(V to G)-myc. Personal communication, Dr. Stacey Huppert.

Systemic oestrogen signalling is mediated by EGFR and Notch. (A) Representative Western blot showing expression of cleaved (active) Notch1 (N1-ICD) following culture ± 1 nM 17β-estradiol ± 10 μM GSI. (Bi) Representative Western blot showing expression of Notch ligands in sorted MCF7 cells (left) and, where available, metastatic cells (right). (Bii) Densitometric analysis of three independent repeats of MCF7 sorting and of a single experiment for primary cells. Comparisons between population 1 (CSC enriched) and other populations are displayed. (C and D) Mammosphere formation was assessed following culture with 1 nM 17β-estradiol ± gamma secretase inhibitor (GSI) alone and in combination with gefitinib. Fold change is normalised to control, untreated cells represented as line. (E) Representative image of protein levels of ERK and phosphorylated (actived) ERK following culture for 48 hours in monolayer ± 10 μM GSI. Means plotted ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001 compared to E2 treated. # P < 0.05 compared to control cells. Figure provided by CiteAb. Source: Breast Cancer Res, PMID: 23497505.

Systemic oestrogen signalling is mediated by EGFR and Notch. (A) Representative Western blot showing expression of cleaved (active) Notch1 (N1-ICD) following culture ± 1 nM 17β-estradiol ± 10 μM GSI. (Bi) Representative Western blot showing expression of Notch ligands in sorted MCF7 cells (left) and, where available, metastatic cells (right). (Bii) Densitometric analysis of three independent repeats of MCF7 sorting and of a single experiment for primary cells. Comparisons between population 1 (CSC enriched) and other populations are displayed. (C and D) Mammosphere formation was assessed following culture with 1 nM 17β-estradiol ± gamma secretase inhibitor (GSI) alone and in combination with gefitinib. Fold change is normalised to control, untreated cells represented as line. (E) Representative image of protein levels of ERK and phosphorylated (actived) ERK following culture for 48 hours in monolayer ± 10 μM GSI. Means plotted ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001 compared to E2 treated. # P < 0.05 compared to control cells. Figure provided by CiteAb. Source: Breast Cancer Res, PMID: 23497505.

Immunofluorescence imaging-based analyses of glomerular sections shows erlotinib administration protects WT and Pod-miR-146a？/？？mice from STZ injury via reduction in ErbB4 and EGFR.？(A)？Representative confocal microscopy images of immunofluorescently labeled glomeruli from WT (top three panels) and Pod-miR146a (bottom three panels) mice treated with vehicle alone (Control), with STZ and vehicle (STZ) or with STZ and erlotinib (STZ Erl). Tissue sections were imaged after staining with DAPI (nuclear marker) and antibodies against ErbB4, EGFR, Notch-1 and Synaptopodin (Synpo, podocyte marker) (as indicated). Scale bar, 50 μm.？(B)？Bar graphs showing quantification of relative glomerular signal intensity of ErbB4, EGFR and Notch-1 in tissue samples from A. Statistics were performed using two-way ANOVA. Data shown are mean ± SEM (n？= 5/group). *p？< 0.05; ***p？< 0.001; ns, no significant difference. Fig 5. PMID:？36059820.